Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kala BIO, Inc.

NASDAQ: KALA · Life Sciences · 4 alerts · CIK 1479419

Share price
$3.83Close, Nov 16
Market cap
$74.1M
Shares outstanding
19.34MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kala BIO, Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Nasdaq/NYSE Compliance Notice

Kala BIO Nasdaq/NYSE Compliance Notice

KALA BIO received a determination from the Nasdaq Hearings Panel granting its request to continue its listing on The Nasdaq Capital Market subject to specific conditions. The company must evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026, and maintain that price through February 23, 2027. Failure to meet these conditions or any other listing rules during this period may result in delisting.

Counterparty
The Nasdaq Stock Market LLC
Term
through Feb 2027
4:26 PM ET 8-K
Reverse Stock Split

Kala BIO Reverse Stock Split

KALA BIO filed a Certificate of Amendment to effect a 1-for-30 reverse stock split of its common stock, effective November 13, 2026. The split will reduce the number of outstanding shares from approximately 19.3 million to approximately 644,659 to meet market requirements. Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market on November 16, 2026.

9:02 AM ET 8-K
Business Update

Kala BIO Business Update

KALA BIO announced preliminary unaudited financial results for the third quarter of 2026, reporting a significantly reduced net loss of $0.8 million compared to $7.6 million in the prior year. The company ended the period with $7.0 million in cash and no debt as it continues its strategic shift toward building an AI infrastructure platform for the biotechnology industry.

4:12 PM ET 8-K
Shareholder Meeting

Kala BIO Shareholder Meeting

KALA BIO held its Annual Meeting of Stockholders on November 3, 2026, where shareholders elected Yonatan Colman and Brendan Purdy as Class III directors. Stockholders also approved an advisory vote on executive compensation, ratified HTL International, LLC as the independent auditor, and authorized a potential reverse stock split at a ratio between 1-for-2 and 1-for-300.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.